Status:
COMPLETED
Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma
Lead Sponsor:
Guangxi Medical University
Collaborating Sponsors:
People's Hospital of Guangxi Zhuang Autonomous Region
Guangxi Sci-Tech Office
Conditions:
Nasopharyngeal Carcinoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
PHASE3
Brief Summary
Based on the radiobiological findings that accelerated tumor repopulation in nasopharyngeal carcinoma occurs in the late-course of radiation therapy, the investigators hypothesize that intensity-modul...
Eligibility Criteria
Inclusion
- Histologically proven non-keratinizing or undifferentiated type nasopharyngeal carcinoma for primary treatment with curative intent
- According to AJCC 2002 Staging System, clinical stage must be Ⅱb-Ⅳb
- Age between 18-70
- Karnofsky performance status ≥70
- WBC ≥4,000/mm3, PLT ≥ 100,000/mm3,serum creatinine ≤ 1.6 mg/dl
- Without radiotherapy or chemotherapy
- Signed study-specific consent form prior to study entry
Exclusion
- Patients with distant metastasis
- Pregnant or lactating women
- The presence of uncontrolled life-threatening illness
- Patients who received radiotherapy or chemotherapy previously
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00778908
Start Date
January 1 2008
End Date
December 1 2011
Last Update
August 21 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
People's Hospital of Guangxi Zhuang Autonomous Region
Nanning, Guangxi, China, 530021